Loading
Luminal androgen receptor is one of the four molecular subtypes of triple-negative breast cancer. Its cells look and behave like hormone-driven luminal cells but run on the androgen receptor instead of oestrogen, which makes them slower growing, less responsive to chemotherapy and the target of trials with prostate cancer drugs.
The LAR subtype was one of six triple-negative expression clusters identified in 587 tumours, characterised by androgen receptor signalling, including patients with decreased relapse-free survival, and with cell lines uniquely sensitive to bicalutamide (Lehmann 2011). It survived the 2016 refinement to four tumour-specific subtypes (BL1, BL2, M and LAR) and had a pathological complete response rate of 29 percent across five neoadjuvant datasets against 41 percent for BL1 and 18 percent for BL2 (Lehmann 2016), and 10 percent in the MD Anderson series (Masuda 2013). Burstein's independent classification also finds an LAR group, with the androgen receptor and MUC1 as candidate targets and a distinct DNA copy number profile (Burstein 2015). The subtype page tnbc-luminal-androgen-receptor carries the overlap with molecular apocrine and histological apocrine carcinoma and the bicalutamide and enzalutamide trials; the androgen receptor-positive term carries the immunohistochemistry thresholds.
In plain words · The hormone switch that drives prostate cancer, attacked by castration and by pills that block the receptor.
Showing the target this term concerns: Androgen receptor.
Shares Luminal androgen receptor triple-negative breast cancer (LAR), Pathologic complete response (pCR), Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Basal-like breast cancer, Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Basal-like breast cancer, Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Pathologic complete response (pCR), Triple-negative breast cancer (TNBC) and the tags breast, tnbc.
Shares Triple-negative breast cancer (TNBC) and the tags breast, tnbc.